RegCell

RegCell is a biotechnology company founded in 2016 that specializes in developing cell-based immunotherapies focused on regulatory T cells (Tregs).

The company aims to restore immune tolerance, particularly for autoimmune diseases and transplantation. Originally a university spinout in Japan, RegCell has since relocated its headquarters to the United States to enhance its global development efforts. The company's primary offering is a proprietary cell-therapy platform known as S/F-Epigen-Tregs, which creates disease-antigen-specific regulatory T cells. This innovative approach is designed to ensure the stability and functionality of Tregs in vivo. Additionally, RegCell is exploring cytotoxic T-cell therapies for cancer, including approaches derived from induced pluripotent stem cells (iPS). The company is actively engaged in research across various immune-regulation disorders, including graft-versus-host disease, allergies, and oncology.